Knight Therapeutics Stock
€4.02
Your prediction
Knight Therapeutics Stock
Pros and Cons of Knight Therapeutics in the next few years
Pros
Cons
Performance of Knight Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Knight Therapeutics | -0.500% | 10.440% | 12.921% | 8.065% | 8.065% | 14.857% | 14.857% |
| MicroPlanet Technology Corp | - | 0.000% | -9.459% | 60.287% | -11.842% | -16.770% | -31.980% |
| Biomark Diagnostics Inc. | -1.810% | 6.536% | 13.986% | 150.769% | 18.116% | 204.673% | 146.970% |
| Avricore Health Inc. | 0.000% | 29.412% | -6.383% | 37.500% | 91.304% | -80.531% | -84.722% |
News
EVP of North America's Largest Full Truckload Company EVP Sells All Insider Shares
Michael K Liu, EVP - Operations at Knight-Swift (NYSE:KNX), disposed of 1,243 directly held shares in an open-market sale on Feb. 4, 2026, fully exiting his direct equity position according to a SEC
Changing Your Dog's Diet May Help the Planet More Than Changing Your Own, Study Finds
LONDON, UK / ACCESS Newswire / February 10, 2026 / Diets high in meat, eggs, and dairy products incur significant environmental costs. But a new study has revealed that, in many cases,
One Fund Just Sold $23 Million of This Major Freight Stock. Here's What Investors Should Know
On February 4, Triton Wealth Management, PLLC reported selling 481,779 shares of Knight-Swift Transportation Holdings (NYSE:KNX), an estimated $22.58 million trade based on quarterly average


